NEW YORK, Sept. 8, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with a focus on cell-based therapeutic development, today announced it is presenting at three upcoming September conferences: the Rodman & Renshaw Annual Healthcare Conference, the Cell Therapy Commercialization Summit, and the JMP Securities Healthcare Conference. "NeoStem's strategic combination of revenues with manufacturing and a global reach has positioned the Company to be a leader in the cell therapy space and we are pleased to share NeoStem updates with industry and the investor community," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. NeoStem will be presenting at the following conferences: Rodman & Renshaw 13th Annual Healthcare Conference- September 11-13, New York, New York11:15 AM on Monday, September 12 at the Waldorf Astoria, New York, NY in the Starlight North room. Cell Therapy Commercialization Summit - September 19-21, Boston, MA11 AM on Monday, September 19 as part of the Cell Therapy Investor Forum, located in the Seaport World Trade Center. 1:45 PM and 4:30 PM on Tuesday, September 20. 6th Annual JMP Securities Healthcare Conference - September 27-29, New York, New YorkWednesday, September 28 at 9 AM at the St. Regis Hotel, New York, NY. About NeoStem, Inc. NeoStem is engaged in the development and manufacturing of cell-based therapies in the U.S. Its January, 2011 acquisition of Progenitor Cell Therapy, and its July 13, 2011 agreement to acquire Amorcyte, Inc. (which is expected to close in the fourth quarter subject to shareholder approval) position NeoStem to achieve its mission of capturing the paradigm shift to cell therapy. PCT not only gives NeoStem access to a world class contract manufacturing cell therapy company, but provides NeoStem a platform and expertise around the evaluation, development and regulatory requirements necessary to develop autologous, allogeneic, immunomodulatory and vaccine-based therapeutics.